The 28th EADV Congress brought innovations to dermatologists in many respects. In this overview, we have attempted to be balanced and to focus on the presentations which are practically relevant. The new insights into the pathogenesis of inflammatory skin diseases have provided biomarkers that are becoming significant to dermatology. Introduction of new treatments in inflammatory dermatoses requires a critical and adequate positioning of new treatments in daily practice.
In particular in psoriasis, the innovations found their way to real clinical practice: In children with psoriasis anti-IL-17 are currently explored. On ixekizumab, 78% of children with psoriasis reached a PASI 90 response. Comorbidities are also relevant to psoriasis. Studies on the efficacy of treatments in comorbid patients was similar to the efficacy in patients without comorbidities. A remarkable study was presented, showing that patients with moderate-to-severe psoriasis treated with adalimumab had a 58% lower standardised mortality rate compared with the general population. Comorbidities matter and evidence is accumulating that adequate treatment of psoriasis may prevent their development. In atopic dermatitis, treatment innovation is a revolution: various JAK inhibitors, anti-IL-4/IL-13, PDE4 inhibitors, and IL-1 alpha blockade.
Furthermore, this overview provides information on: photo-protection by systemic treatment, comorbidities in urticaria, and a “tracker” to classify rosacea by phenotype, which makes sense as a subdivision in light of treatment selection. The future for inflammatory dermatoses of the skin is bright.
Prof. Peter C.M. van de Kerkhof
Peter C.M. van de Kerkhof is emeritus Professor of Dermatology and immediate past chairman of the Department of Dermatology of Radboud University Nijmegen. He is currently the coordinating Medical Officer of the International Psoriasis Council and chair of the scientific advisory board of the Dutch burn association. He has been working for many years on the pathogenesis and treatment of psoriasis. He has published more than 700 publications in peer-reviewed journals and has given many presentations on invitation at international conferences. He has served as president of the ESDR, EDF, and the International Psoriasis Council, and was board member of various international societies. Current interests are: pathogenesis and development of biomarkers for psoriasis; real clinical practise research; and personalised medicine.
Conflict of Interest Statement:
Consultancy services for: Celgene, Almirall, Amgen, Pfizer, Philips, AbbVie, Eli Lilly, Galderma, Novartis, Janssen Biotech, Janssen-Cilag, LEO Pharma, Sandoz, Mitsubishi Tanabe, Sandoz, Bristol Meyer Squibb, UCB, Dermavant. Speaker services for: Celgene, Almirall, Eli Lilly, Novartis, Jansen-Cilag, LEO Pharma, Sandoz, Bristol Meyer Squibb.
« Inflammation may change the course of Parkinson’s disease Next Article
No hint of teratogenicity through ixekizumab »
Table of Contents: EADV 2019
Letter from the Editor
IL-17A blocker effective in paediatric psoriasis patients
Rituximab beats mycophenolate mofetil in pemphigus vulgaris
Novel JAK1/2 inhibitor shows remarkable efficacy in alopecia areata
Acne highly influenced by climate, pollutants, and unhealthy diet
JAK inhibition plus TCS lead to high clearance rates in AD
No cancer risk with long-term use of tacrolimus, a topical calcineurin inhibitor, in children with AD
Green light for a second JAK inhibitor in AD
Topical ruxolitinib effective in vitiligo
Small molecules: interesting novel treatment options in AD
IL-1⍺ blockade: a new treatment option in AD
IL-4/IL-13 blockade leads to rapid itch reduction in adolescents
How to manage conjunctivitis in AD patients treated with a biologic
Biologics: increasingly used in paediatric dermatology
Spotlight on Psoriasis
IL-17 blocker: effective and safe in patients with comorbidities
ESPRIT registry: sharp decline in mortality in patients treated with a TNF blocker
Relationship psoriasis and NAFLD: new data on the hepato-dermal axis
Novel selective IL-23 blocker equally effective in patients with metabolic syndrome
Selective IL-23 blocker crushes fumaric acids in all assessed efficacy endpoints
No hint of teratogenicity through ixekizumab
New Insights in Photoprotection
Systemic photoprotection: a valuable addition to topical sun protection
The underestimated effect of visible light
Comorbidities more common in chronic urticaria, psoriasis, and AD
D-Dimer as future biomarker in CSU management?
Ligelizumab for CSU: symptom control and high response rates in re-treatment
Rosacea – From New Spectrum to New Therapy
New guidance on rosacea therapy according to phenotype
Best of the Posters
Above-the-neck melanoma more prone to metastases
Reduced sleep quality in dermatoses influenced by itch and pain
Anxiety and depression are common in families of AD infants
Certolizumab pegol efficacious for head and neck psoriasis
ABP501 biosimilar for adalimumab: What you need to know